Hebei Yuyi Pharmaceutical'sipatasibanaiepego has been approved by the CDE for the treatment of advanced liver cancer, a breakthrough therapy designation.

On May 26th, He Yu Pharmaceuticals announced that its independently developed highly selective small molecule FGFR4 inhibitor, Hepagotinib, has been granted Breakthrough Therapy designation by the National Medical Products Administration Drug Evaluation Center for the treatment of hepatocellular carcinoma. Hepagotinib is the first targeted molecular biomarker precision therapy for hepatocellular carcinoma.